Hughes, R. Dalakas, M.C. Merkies, I. Latov, N. Léger, J.-M. Nobile-Orazio, E. Sobue, G. Genge, A. Cornblath, D. Merschhemke, M. Ervin, C.M. Agoropoulou, C. Hartung, H.-P. Day, T. Spies, J. Roberts, L. Van Damme, P. Van den Bergh, P.Y. Maertens de Noordhout, A. Dionne, A. Larue, S. Massie, R. Melanson, M. Camu, W. De Seze, J. Le Masson, G. Pouget, J. Schmidt, J. Kimiskidis, V.K. Chapman, J. Drory, V.E. Fazio, R. Gallia, F. Kusunoki, S. Mori, M. Iijima, M. Okamoto, T. Baba, M. Faber, C.G. van Schaik, I.N. Fryze, W. Motta, E. Selmaj, K. Casasnovas, C. Sola, A.G. Illa, I. Holt, J. Miller, J.A. Lunn, M.P. Brannagan, T.H., III Brown, M. Kelemen, J. Iyadurai, S. Rezania, K. Sharma, K.R. Tandan, R. Gudesblatt, M. Lawson, V. Amato, A.A. FORCIDP Trial Investigators, Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial, The Lancet Neurology, (17), 689-698, 2018, The Lancet Publishing Group,